Roivant Sciences (ROIV) Operating Expenses (2020 - 2026)

Roivant Sciences (ROIV) has 6 years of Operating Expenses data on file, last reported at $936.0 million in Q4 2025.

• Quarterly Operating Expenses rose 10.1% year-over-year to $936.0 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $1.5 billion (up 8.04% YoY) and the FY2026 annual result came in at $1.3 billion, up 13.2% from the prior year.
• Operating Expenses rose to $936.0 million in Q4 2025, from $307.8 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $1.1 billion in Q4 2021 to a low of $162.1 million in Q2 2021.
• A 5-year average of $511.9 million and a median of $307.8 million in 2025 frame the typical range for Operating Expenses.
• Annual changes were most pronounced in 2021 — Operating Expenses jumped 342.42% — and 2022, when it slumped 58.01%.
• Tracing ROIV's Operating Expenses over 5 years: stood at $1.1 billion in 2021, then dropped by 13.78% to $975.1 million in 2022, then plunged by 31.47% to $668.2 million in 2023, then grew by 27.23% to $850.2 million in 2024, then rose by 10.1% to $936.0 million in 2025.
• The last three Operating Expenses figures came in at $936.0 million (Q4 2025), $307.8 million (Q3 2025), and $287.1 million (Q2 2025), per Business Quant data.